| Gene name: | AKT1 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | Primary leiomyoma cell |
| Gene ID: | 207 |
| Category: | protein coding |
| Phenotype: | Uterine leiomyomas |
| Experimental category: | L |
| PMID: | 24476133 |
| Experiment: | SA-β-gal activity assay//qPCR |
| Description: | The percentage of β-galactosidase stained DDHLM and primary leiomyoma cells with MK-2206 treatment were significantly higher than untreated cells.Approximately 32% of cells exhibited SAHF when treated with MK-2206 compared to 8% in control cells. When leiomyoma cells were treated with MK-2206, the senescence associated genes,P16,P21 and P53 were significantly upregulated . |
| Target gene: | MIR-182//MIR-200//HMGA2 |
| Official symbol(s): | MIR-182//MIR-200//HMGA2 |
| R-AG-Target gene: | --//--//-- |
| Subcategory: | Unclear |
| Target gene experiment: | Immunofluorescence//qPCR |
| Target gene description: | In response to MK-2206 as well as the dual PI3K/mTOR inhibitor, BEZ235, ROS levels increased in primary leiomyoma cells. Similarly,miR-182 and miR-200a/c expression increased in leiomyoma cells treated with MK2206 in a dose-dependent manner.HMGA2 expression was significantly increased in a dose-dependent manner when AKT was inactivated by MK-2206. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...